✦ LIBER ✦

A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma

✍ Scribed by Nowak, Anna K.; Brown, Chris; Millward, Michael J.; Creaney, Jenette; Byrne, Michael J.; Hughes, Brett; Kremmidiotis, Gabriel; Bibby, David C.; Leske, Annabell F.; Mitchell, Paul L.R.; Pavlakis, Nick; Boyer, Michael; Stockler, Martin R.

Book ID: 121655162
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 632 KB
Volume: 81
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2013.05.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-620 An update of pemetrexed (P) plus g

P-620 An update of pemetrexed (P) plus gemcitabine (G) asfront-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial

✍ Janne, P.; Simon, G.; Langer, C.; Taub, R.; Dowlati, A.; Fidias, P.; Bloss, L.; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 124 KB

Pemetrexed Versus Pemetrexed and Carbopl

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

✍ Ardizzoni, A.; Tiseo, M.; Boni, L.; Vincent, A. D.; Passalacqua, R.; Buti, S.; A 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 200 KB

P-488 Phase II randomized trial of singl

P-488 Phase II randomized trial of single-agent pemetrexed orsequentially administered pemetrexed/gemcitabine as front-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in elderly patients or patients ineligible for platinum-based chemotherapy

✍ Gridelli, C.; Reck, M.; Gregorc, V.; Migliorino, M.; Muller, T.; Manegold, C.; F 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 140 KB